1. Home
  2. SLS vs LPRO Comparison

SLS vs LPRO Comparison

Compare SLS & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • LPRO
  • Stock Information
  • Founded
  • SLS 2012
  • LPRO 2000
  • Country
  • SLS United States
  • LPRO United States
  • Employees
  • SLS N/A
  • LPRO N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • LPRO Finance: Consumer Services
  • Sector
  • SLS Health Care
  • LPRO Finance
  • Exchange
  • SLS Nasdaq
  • LPRO Nasdaq
  • Market Cap
  • SLS 238.7M
  • LPRO 252.9M
  • IPO Year
  • SLS N/A
  • LPRO N/A
  • Fundamental
  • Price
  • SLS $1.92
  • LPRO $1.82
  • Analyst Decision
  • SLS Strong Buy
  • LPRO Buy
  • Analyst Count
  • SLS 1
  • LPRO 6
  • Target Price
  • SLS $7.00
  • LPRO $3.00
  • AVG Volume (30 Days)
  • SLS 4.7M
  • LPRO 679.2K
  • Earning Date
  • SLS 11-12-2025
  • LPRO 11-06-2025
  • Dividend Yield
  • SLS N/A
  • LPRO N/A
  • EPS Growth
  • SLS N/A
  • LPRO N/A
  • EPS
  • SLS N/A
  • LPRO N/A
  • Revenue
  • SLS N/A
  • LPRO $16,254,999.00
  • Revenue This Year
  • SLS N/A
  • LPRO $306.78
  • Revenue Next Year
  • SLS N/A
  • LPRO $11.69
  • P/E Ratio
  • SLS N/A
  • LPRO N/A
  • Revenue Growth
  • SLS N/A
  • LPRO N/A
  • 52 Week Low
  • SLS $0.77
  • LPRO $0.70
  • 52 Week High
  • SLS $2.48
  • LPRO $6.92
  • Technical
  • Relative Strength Index (RSI)
  • SLS 51.34
  • LPRO 42.89
  • Support Level
  • SLS $1.86
  • LPRO $1.82
  • Resistance Level
  • SLS $2.06
  • LPRO $1.98
  • Average True Range (ATR)
  • SLS 0.16
  • LPRO 0.12
  • MACD
  • SLS -0.02
  • LPRO -0.01
  • Stochastic Oscillator
  • SLS 11.90
  • LPRO 31.94

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About LPRO Open Lending Corporation

Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.

Share on Social Networks: